{
  "compound": "Cannabis extract (THC:CBD) or synthetic THC (Marinol)",
  "condition": "MULTIPLE_SCLEROSIS",
  "effect_size": "Medium for subjective (d=0.62), small for objective (d=0.21)",
  "study_type": "RCT",
  "source": "NORML:MS_RCT_002",
  "participants": "667 MS patients (largest cannabinoid MS trial)",
  "year": 2003,
  "notes": "Cannabinoids for Treatment of Spasticity and Other Symptoms Related to MS (CAMS Study)",
  "confidence": "medium",
  "abstract": "No significant difference on Ashworth; BUT patient-reported spasticity improved 61% (p<0.001); mobility improved; pain reduced 42%"
}